Precision medicine

Precision Medicine Asia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic Screening Platform for the Asia-Pacific Region

Retrieved on: 
Wednesday, December 21, 2022

TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

Key Points: 
  • TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.
  • LC-SCRUM-AP is a genomic screening platform for patients with advanced or recurrent non-small cell lung cancer.
  • The aim is to further develop precision medicine in Asia by establishing a genomic screening infrastructure for the Asia-Pacific region.
  • The integration of the LC-SCRUM-Asia and LC-SCRUM-AP databases will create an international, large-scale lung cancer clinicopathological database and contribute to the development of precision medicine in Asia.

HTG Announces One-for-Twelve Reverse Stock Split

Retrieved on: 
Tuesday, December 20, 2022

HTG’s common stock will continue to trade under the ticker symbol “HTGM.”

Key Points: 
  • HTG’s common stock will continue to trade under the ticker symbol “HTGM.”
    As a result of the reverse stock split, each twelve pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock.
  • No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split.
  • Stockholders of record will receive information regarding their share ownership from HTG’s transfer agent, American Stock Transfer & Trust Company, LLC.
  • For additional information regarding the reverse stock split, please refer to HTG’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 20, 2022.

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Retrieved on: 
Monday, December 19, 2022

Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management.

Key Points: 
  • Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management.
  • He most recently served as the CMO and founding team member at Sema4 Holdings Corp.
    Lisa Olson-Coombe recently joined Myriad as VP of Lab Transformation.
  • They are all accomplished leaders who will each play an instrumental role in accelerating the growth of our commercial business forward and elevating our products to their full potential,” said Paul J. Diaz, president and CEO, Myriad Genetics.
  • “Their combined depth of experience in healthcare and respective areas of expertise will continue to enrich our strong foundation for long-term sustainable growth, profitability and innovation.”

Bioinformatics Global Market Report 2022: Increasing Public and Private-Sector Funding for Bioinformatics to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023

The growth of the bioinformatics market is driven by the increasing public and private-sector funding for bioinformatics, growing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure, and decreasing cost of genome sequencing.

Key Points: 
  • The growth of the bioinformatics market is driven by the increasing public and private-sector funding for bioinformatics, growing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure, and decreasing cost of genome sequencing.
  • Based on product & service, the bioinformatics market is segmented into knowledge management tools, bioinformatics platforms, and bioinformatics services.
  • In 2021, the knowledge management tools segment accounted for the largest share of 36.3% of the bioinformatics market.
  • Many major global players are also based in the US, owing to which the country has become a center of innovation in the bioinformatics market.

QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases

Retrieved on: 
Thursday, January 5, 2023

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.

Key Points: 
  • QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
  • As the development of precision medicines accelerates, so does the need for companion diagnostics devices and tests detecting clinically relevant genetic abnormalities.
  • Principally used in oncology to date, companion diagnostics that employ whole exome sequencing are widely believed to have great potential in hereditary disease areas such as cardiovascular, metabolic, neuro-degenerative, and auto-immune diseases.
  • Under the agreement announced today, QIAGEN will be the exclusive marketing and contracting partner in the U.S. for Helix’s companion diagnostic services.

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization

Retrieved on: 
Thursday, January 5, 2023

InterVenn Biosciences, the life science company pioneering glycoproteomics co-founded by Nobel Prize winner Carolyn Bertozzi, PhD, Carlito Lebrilla, Ph.D., and Aldo Carrascoso, today announced changes to its senior management team to support its commercialization execution.

Key Points: 
  • InterVenn Biosciences, the life science company pioneering glycoproteomics co-founded by Nobel Prize winner Carolyn Bertozzi, PhD, Carlito Lebrilla, Ph.D., and Aldo Carrascoso, today announced changes to its senior management team to support its commercialization execution.
  • “From the beginning, Genoa has been on the journey with InterVenn to realize the exceptional potential of glycoproteomics to provide necessary specificity for precision medicine applications.
  • Estigarribia takes on the CEO role at InterVenn as the company’s platform is ready for commercialization.
  • Estigarribia and his team will expand the market applications of the platform as well as the scope of partnering capabilities.

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Retrieved on: 
Thursday, January 5, 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study ( NCT05257551 ), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC).

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study ( NCT05257551 ), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC).
  • The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment.
  • In the United States, lung cancer is the second most common cancer, and approximately 13% of people diagnosed with lung cancer have SCLC , according to the American Cancer Society.
  • To date, there are limited ways to stratify this specific patient population and limited defined therapeutic targets or associated treatments.

Onc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture Capital

Retrieved on: 
Thursday, January 5, 2023

Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund).

Key Points: 
  • Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund).
  • Also participating were Life Extension Ventures and all existing investors including Blue Venture Fund, Accomplice, Digitalis Ventures, and KdT Ventures.
  • New investor Action Potential Venture Capital invests in companies advancing the fields of bioelectronic medicines, and enabling technologies for precision medicine.
  • “On behalf of the company and existing investors, I would like to welcome MassMutual Alternative Investments and Action Potential Venture Capital as we work together to improve oncology clinical management in a significant way.

Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research

Retrieved on: 
Wednesday, January 4, 2023

Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.
  • The acquisition complements Agilent’s market-leading SureSelect portfolio and further augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets.
  • The chemistries and assays from Avida Biomed are compatible with Agilent’s automation platforms including Magnis and Bravo, which will facilitate efficient scaling of research experiments and routine sample testing.
  • Avida Biomed’s innovative genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity.

Fulgent Expands Board of Directors with Addition of Reggie Groves

Retrieved on: 
Tuesday, January 3, 2023

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.
  • “Reggie possesses a diverse business skill set and a global perspective that we believe will be invaluable to Fulgent’s Board of Directors, as we enter a new chapter in precision medicine with our recent acquisition of Fulgent Pharma,” said Ming Hsieh, Chairman and Chief Executive Officer of Fulgent Genetics.
  • Ms. Groves is a C-level executive experienced in working with and serving on Boards.
  • “I am excited to join Fulgent’s Board of Directors,” said Ms. Reggie Groves.